Navigation Links
Xencor, Inc. Announces Closing of Initial Public Offering

MONROVIA, Calif., Dec. 6, 2013 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the closing of its initial public offering of 14,639,500 shares of its common stock at an initial public offering price of $5.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,909,500 additional shares of common stock. Xencor's common stock is listed on The NASDAQ Global Market under the trading symbol "XNCR." All of the shares in the offering were offered by Xencor. Xencor estimates net proceeds from the offering to be approximately $72.4 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Credit Suisse Securities (USA) LLC and Leerink Swann LLC are acting as joint book-running managers of the offering. Wedbush PacGrow Life Sciences is acting as a co-manager for the offering.

A registration statement relating to the securities being sold in this offering was declared effective by the U.S. Securities and Exchange Commission on December 2, 2013. The offering was made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by calling toll-free (800) 221-1037, or by emailing; or Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by email at, or by phone at (800) 808-7525.

This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, five antibodies are in clinical development internally and with partners that have been engineered with Xencor's XmAb technology.  Xencor's internally-discovered programs include XmAb5871, in Phase 1b/2a clinical trials for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in preclinical development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC and Boehringer Ingelheim.

SOURCE Xencor, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
2. Concord Medical Announces the Closing of Acquisition of Its Shares by CEO and COO from Other Shareholders
3. Osseon Announces New Regional Sales Director
4. UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Against ARIAD Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ARIA
5. EarlySense Announces Patient Rest Indicator for Better Patient Supervision at Night
6. Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder
7. Cyberonics Announces Expansion of Share Repurchase Program By An Additional One Million Shares
8. Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
9. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy and other Neurological Disorders
10. Soligenix Announces Initiation of a Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
11. MiMedx Announces Next Steps After Discussions With The FDA
Post Your Comments:
(Date:11/30/2015)... Calif. , Nov. 30, 2015 /PRNewswire/ ... today that Matt Hogan , Chief ... Oppenheimer Healthcare Conference on Tuesday, December 8 ... is being held at the Westin Grand ... also be available for one-on-one meetings at ...
(Date:11/30/2015)... , Nov. 30, 2015 Next week, December ... of Things (DoT ) co-located events covering the latest ... Internet of Things, will draw more than 3,000 design ... Convention Center. The events, combined show floor will ... --> --> ...
(Date:11/30/2015)... Nautilus Medical Inc. today announced worldwide availability of MatrixRay, ... The release of MatrixRay to the entire medical healthcare ... America) in Chicago - the ... --> --> MatrixRay is the first ... worldwide via a peer-to-peer exchange network of physicians and ...
Breaking Medicine Technology:
(Date:11/30/2015)... MN (PRWEB) , ... December 01, 2015 , ... ... is the latest carrier to offer individual vision insurance plans on ... the unique ability to rate and review products, allowing consumers to compare, quote ...
(Date:11/30/2015)... ... 2015 , ... During the National Family Caregivers Month, the ... webinars on topics of ‘Medical and Palliative Care Decisions,’ and ‘Self-Care for Caregivers.’ ... , With a loved one's diagnosis of mesothelioma, the closest family member is ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... surgery and dermatology, is proud to announce that its ThermiRFR temperature controlled radiofrequency ... ThermiRF is an innovative multi-application radiofrequency platform which uses temperature as a clinical ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... this summer, ushering in a new era of publicly accessible automated technology. Now, ... will continue to offer guests an up-close look at the shuttle at MOSI’s ...
(Date:11/30/2015)... ... 30, 2015 , ... On Saturday, October 24th, 2015, at the Mill Race ... event, a 5K walk known as “Making Strides Against Breast Cancer”. Patients and staff ... also located in Battle Creek, joined in for this campaign that sought to raise ...
Breaking Medicine News(10 mins):